Liquid biopsy is a minimally invasive technology for detection of molecular biomarkers without the need for high priced or invasive processes. It’s an easy and non-invasive alternative to surgical biopsies which allows scientific medical doctors to find out a variety of statistics about a ailment or a tumor through a easy blood pattern. Circulating most cancers cells or lines of the cancer’s RNA or DNA in the blood can provide clues about which remedies are most likely to paintings for that affected person. Circulating nucleic acids are protected with the aid of extracellular micro-vesicles, especially exosomes. A test accomplished on a pattern of blood to search for cancer cells from a tumor that are circulating within the blood or for portions of DNA from tumor cells that are in the blood. A liquid biopsy may be used to assist locate cancer at an early degree. It may additionally be used to help plan treatment or to discover how nicely remedy is working or if cancer has come lower back.
How Big is the Global Liquid Biopsy Market?
The Global Liquid Biopsy Market is expected to be around US$ 6.80 billion by 2028 and will grow at a CAGR of more than 23% in the given forecast period.
The major driving factors of Global Liquid Biopsy Market are as follows:
The restraining factors of Global Liquid Biopsy Market are as follows:
The Global Liquid Biopsy Market is segmented on the lines of its type of cancer, product and service, circulation biomarkers, end user and regional. Based on type on cancer it covers lung cancer, colorectal cancer, prostate cancer, breast cancer, liver cancer and other cancers. Product and service is classified into instruments, services and software and reagents. Under circulation biomarkers it covers circulating tumor cells, extracellular vesicles, circulating tumor DNA and other biomarkers. End user segment is classified into academic & research centers, reference laboratories, hospital and physician laboratories and others end user. The Global Liquid Biopsy Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Liquid Biopsy and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Global Liquid Biopsy Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets for Global Liquid Biopsy Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players
The Global Liquid Biopsy Market has been segmented as below:
By Type of Cancer Analysis
By Product and services Analysis
By Circulation Biomarkers Analysis
By End User Analysis
By Regional Analysis
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Global Liquid Biopsy Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Liquid Biopsy Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our new reports:
Electronic Control Dental Chair market
Electronic Veterinary Thermometers market
1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
2 Research Methodology
2.1 Liquid Biopsy Market Size Estimation
2.2 Liquid Biopsy Market Breakdown and Data Triangulation
2.2.1 Key Data From Secondary Sources
2.2.2 Key Data From Primary Sources
2.2.3 Assumptions for the Study
3 Executive Summary
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion
4 Premium Insights
4.1 Liquid Biopsy: Market Overview
4.2 Geographic Analysis: Liquid Biopsy Market, By Circulating Biomarker
4.3 Liquid Biopsy Market Size, By End User, 2019 vs 2025
4.4 Liquid Biopsy Market Size, By Product, 2019 vs 2025
4.5 Liquid Biopsy Market Size, By Circulating Biomarker, 2019 vs 2025
4.6 Geographical Snapshot of the Liquid Biopsy Market
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Increasing Number of New Cancer Cases
5.2.1.2 Benefits of Liquid Biopsy Over Surgical Biopsy
5.2.1.3 Technological Advancements to Boost Market Growth
5.2.1.4 Availability of Funding for Liquid Biopsy Research
5.2.1.5 Initiatives to Increase Awareness on Liquid Biopsy
5.2.2 Market Restraints
5.2.2.1 Low Sensitivity and Specificity
5.2.3 Market Opportunities
5.2.3.1 Focus on Inorganic Strategies
5.2.4 Market Challenges
5.2.4.1 Unclear Regulatory and Reimbursement Scenario
6 Industry Insights
6.1 Introduction
6.2 Regulatory Approval Process
6.3 Major Ongoing Clinical Trials in the Market
6.4 Major Funding Activities in the Market
7 Liquid Biopsy Market, By Cancer Type
7.1 Introduction
7.1.1 Lung Cancer
7.2 Breast Cancer
7.2.1 Colorectal Cancer
7.2.2 Prostate Cancer
7.2.3 Liver Cancer
7.2.4 Other Cancers
8 Liquid Biopsy Market, By Circulating Biomarker
8.1 Introduction
8.2 Circulating Tumor Cells
8.3 Extracellular Vesicles
8.4 Circulating Tumor DNA (CTDNA)
8.5 Other Biomarkers
9 Liquid Biopsy Market, By Products and Services
9.1 Introduction
9.1.1 Reagents
9.2 Instruments
9.2.1 Services & Software
10 Liquid Biopsy Market, By End User
10.1 Introduction
10.2 Reference Laboratories
10.2.1 Hospitals and Physician Laboratories
10.2.2 Academic and Research Centers
10.2.3 Other End Users
11 Liquid Biopsy Market, By Region
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.4 Asia-Pacific
11.5 Rest of the World (RoW)
12 Competitive Landscape
12.1 Overview
12.2 Competitive Situation and Trends
12.2.1 Agreements, Partnerships, and Collaborations
12.2.2 New Product Launches
12.2.3 Acquisitions
12.2.4 Other Developments
13 Company Profiles
13.1 Introduction
13.2 Biocept, Inc.
13.3 Qiagen
13.4 F. Hoffmann-La Roche AG
13.5 Bio-Rad Laboratories Inc.
13.6 Myriad Genetics
13.7 Janssen Diagnostics, LLC.
13.8 Tr0vagene Inc.
13.9 Guardant Health Inc.
13.10 Fraunhofer-Gesellschaft
13.11 MDX Health SA
The Global Liquid Biopsy Market has been segmented as below:
By Type of Cancer Analysis
By Product and services Analysis
By Circulation Biomarkers Analysis
By End User Analysis
By Regional Analysis
SUBSCRIBE TO OUR NEWSLETTERS
